Abstrak 
TB Drugs Development: What’s In The Pipeline
TB Drugs Development: What’s In The Pipeline
Rovina Ruslami, MD.,Ph.d
Universitas Padjadjaran, Presented as a Speaker The 5th International Eijkman Conference Jakarta, 8-10 November 2011
Bahasa Inggris
Universitas Padjadjaran, Presented as a Speaker The 5th International Eijkman Conference Jakarta, 8-10 November 2011
tuberculosis (TB)
Rovina Ruslami, MD.,Ph.d
Universitas Padjadjaran, Presented as a Speaker The 5th International Eijkman Conference Jakarta, 8-10 November 2011
Bahasa Inggris
Universitas Padjadjaran, Presented as a Speaker The 5th International Eijkman Conference Jakarta, 8-10 November 2011
tuberculosis (TB)
Why tuberculosis (TB)? TB is an old, transmittable, but curable disease. Current treatment of TB is based on drugs that are found over 40 years ago. Actually this current treatment is highly efficacious for DS-TB cases, but it is still inadequate in many aspects: the regimen of treatment is complex and long; and to ensure the successful of treatment, it needs a good adherence. The picture becomes more complicated in patients who were infected by drug-resistant mycobacterium tuberculosis (Mtb) organism; in the patients with TB-HIV co-infection; in pediatric TB patients. Not forget to mention that one-third of populations of the world are infected by latent TB.
Download: .Full Papers